Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03671889
Recruitment Status : Recruiting
First Posted : September 14, 2018
Last Update Posted : September 25, 2020
Sponsor:
Information provided by (Responsible Party):
InSightec

Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).

Condition or disease Intervention/treatment Phase
Alzheimer Disease Device: Blood Brain Barrier (BBB) Disruption Not Applicable

Detailed Description:
This is a prospective, multi-center, single-arm study to evaluate the safety and efficacy of BBB disruption using the ExAblate Model 4000 Type 2.0 (220 kHz) system. Patients with diagnosis of Probable Alzheimer's Disease may qualify for a clinical trial to have three serial ExAblate BBB disruption procedures in specific areas in the brain. This study will be conducted at up to 4 sites in the United States and will enroll up to 20 patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Intervention Model Description: Subjects who meet study eligibility will undergo treatment procedures in groups by staged volumes.
Masking: None (Open Label)
Primary Purpose: Device Feasibility
Official Title: Assessment of Safety and Efficacy of ExAblate Blood-Brain Barrier Disruption for the Treatment of Patients With Probable Alzheimer's Disease
Actual Study Start Date : September 28, 2018
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Blood Brain Barrier (BBB) Disruption
ExAblate Model 4000 Type 2.0 System
Device: Blood Brain Barrier (BBB) Disruption
Focal Ultrasound (FUS) involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct targets to induce BBB disruption.
Other Name: ExAblate Neuro




Primary Outcome Measures :
  1. Device and procedure related adverse events [ Time Frame: 5 years ]
    Rate of adverse events following each treatment through end of study


Other Outcome Measures:
  1. BBB Disruption and Closure [ Time Frame: Immediately after the end of each ExAblate treatment and 24 hours post treatment ]
    MR images post-procedure to verify that the BBB was disrupted and subsequently closed within 24 hours.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or Female between 50-85 years of age
  2. Probable Alzheimer's Disease (AD)
  3. If taking concurrent Alzheimer's medication, has been on the medication for at least 2 months with a stable dose for at least 3 months
  4. Able to communicate sensations during the ExAblate MRgFUS procedure
  5. Ambulatory

Exclusion Criteria:

  1. MRI Findings
  2. Presence of unknown or MR unsafe devices anywhere in the body
  3. Significant cardiac disease or unstable hemodynamic status
  4. Relative contraindications to ultrasound contrast agent or PET amyloid tracer
  5. History of a bleeding disorder
  6. History of liver disease
  7. Known cerebral or systemic vasculopathy
  8. Significant depression and at potential risk of suicide
  9. Any contraindications to MRI scanning
  10. Any contraindication to lumbar puncture for collection of cerebral spinal fluid
  11. Untreated, uncontrolled sleep apnea
  12. History of seizure disorder or epilepsy
  13. Severely Impaired renal function
  14. Currently in a clinical trial involving an investigational product or non-approved use of a drug or device or in any other type of medical research
  15. Chronic pulmonary disorders
  16. Positive human immunodeficiency virus (HIV)
  17. Known apolipoprotein E allele (ApoE4) homozygosity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03671889


Locations
Layout table for location information
United States, New York
Weill Cornell Medicine Recruiting
New York, New York, United States, 10065
Contact: Marissa Michael    212-746-7373    mam4001@med.cornell.edu   
Principal Investigator: Michael Kaplitt, M.D., PhD         
United States, Ohio
The Ohio State University -Wexner Medical Center Recruiting
Columbus, Ohio, United States, 43210
Contact: Josh Bolender    614-685-8622    Joshua.Bolender@osumc.edu   
Principal Investigator: Vibhor Krishna, MD         
United States, West Virginia
West Virginia University Rockefeller Neuroscience Center Recruiting
Morgantown, West Virginia, United States, 26506
Contact: Barbara Harring    304-293-9638    barbara.harring@hsc.wvu.edu   
Principal Investigator: Ali R Rezai, MD         
Sponsors and Collaborators
InSightec
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: InSightec
ClinicalTrials.gov Identifier: NCT03671889    
Other Study ID Numbers: AL002
First Posted: September 14, 2018    Key Record Dates
Last Update Posted: September 25, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Keywords provided by InSightec:
Alzheimer Disease
Alzheimer Syndrome
Magnetic Resonance guided Focal Ultrasound (MRgFUS)
Blood-Brain Barrier
ExAblate
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders